

Rising Genetic Disorders Fuel Tay-Sachs Treatment Market Growth in 2025 with Advancements in Research

The Business Research Company's Rising Genetic Disorders Fuel Tay-Sachs Treatment Market Growth in 2025 with Advancements in Research

LONDON, GREATER LONDON, UNITED KINGDOM, March 28, 2025
/EINPresswire.com/ -- Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.



Recent developments in the tay-sachs disease treatment market have seen significant growth, with the market size expanding from \$2.28 billion in 2024 to an expected \$2.45 billion in 2025. This represents a compound annual growth rate CAGR of 7.5%. This leap within the historic period is attributed to an increase in genetic screening, heightened focus on rare diseases, an



It will grow to \$3.25 billion in 2029 at a compound annual growth rate (CAGR) of 7.3%.

The Business Research
Company

increased demand for quality healthcare, a rise in taysachs disease instances, and a surge in chronic condition cases.

What does the future hold for the Tay Sachs Disease Treatment Market?

Looking ahead, the tay-sachs disease treatment market is predicted to experience robust growth in the coming years.

In particular, it is expected to expand to \$3.25 billion by 2029, reflecting a compound annual growth rate CAGR of 7.3%. Numerous factors are contributing to this upcoming growth trajectory. Such factors include increased occurrences of lysosomal storage disorders, raised awareness initiatives, the expansion of genetic testing services, growing demand for symptomatic treatments, and a rising prevalence of genetic diseases. Additionally, major trends that will characterize this forecast period include advancements in gene therapy, cost-effective next-generation sequencing, automated cloning platforms, developments in drug delivery systems, integration of AI and machine learning, and the adoption of telemedicine solutions.

Get Your Free Sample Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=21295&type=smp

What catalysts will drive the growth of the tay-sachs treatment market?

The escalating prevalence of genetic diseases is anticipated to drive the market for tay-sachs disease treatment moving forward. A genetic disease is a disorder caused by abnormalities in an individual's DNA, either inherited or developed due to spontaneous mutations. These diseases are on the rise due to advancements in diagnostics, increased awareness, environmental influences, and increased mutation rates from delayed parenthood and lifestyle changes. This heightened prevalence of genetic diseases underscores the necessity for advancements in tay-sachs disease treatment, stimulating research in gene therapy, enzyme replacement, and early diagnostics. For example, Genomics England, a government organization based in the UK, reported in February 2022 that over 7,000 recognized rare diseases exist, impacting approximately 1 in 17 people 3.5 million in the UK. Therefore, this increasing prevalence of genetic diseases will drive the growth of the tay-sachs disease treatment market.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/tay-sachs-disease-treatment-global-market-report

Who are the leading players in the Tay Sachs Disease Treatment Market?

Key industry players in the tay-sachs disease treatment market include Pfizer Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Amicus Therapeutics Inc., Spark Therapeutics Inc., Rocket Pharmaceuticals Inc., RegenxBio Inc., Forge Biologics Inc., Passage Bio Inc., Protalix BioTherapeutics Inc., Orchard Therapeutics plc, Affinia Therapeutics Inc., IntraBio Inc., and Taysha Gene Therapies Inc.

What are recent trends among Tay Sachs Disease market leaders?

The most recent trend in the tay-sachs disease treatment market revolves around the creation of innovative treatments. Key companies are investing heavily in clinical trials to explore innovative therapies such as gene therapy, enzyme replacement, and small-molecule drugs for improved patient outcomes. For instance, in July 2024, IntraBio Inc., a US-based biopharmaceutical company, announced that it had received US Food and Drug Administration FDA approval for its Investigational New Drug IND Application. The trial, named IB1001-202, focuses on IB1001 and targets GM2 Gangliosidosis Tay-Sachs and Sandhoff Disease. Undertaken in the U.S., UK, Germany, and Spain, the trial aims to tackle these fatal neurodegenerative disorders that currently have no approved treatments, underlining the urgency of developing effective

therapies.

How is the Tay Sachs Disease Treatment Market segmented?

The tay-sachs disease treatment market is categorized based upon the following segments and subsegments:

- 1 By Treatment: Medication, Respiratory Care, Physical Therapy
- 2 By Mode Of Administration: Injectable, Oral, Other Mode Of Administration
- 3 By End-Users: Hospitals, Homecare, Specialty Clinics Subsegments:
- 1 By Medication: Antiepileptic Drugs, Miglustat, Supportive Symptomatic Medications
- 2 By Respiratory Care: Mechanical Ventilation, Airway Clearance Therapy, Oxygen Therapy
- 3 By Physical Therapy: Motor Function Exercises, Hydrotherapy, Assistive Mobility Devices

What are the regional insights of the Tay Sachs Disease Treatment Market?

North America held the largest market share in the tay-sachs disease treatment market in 2024. However, the forecast period is expected to observe Asia-Pacific as the fastest-growing region. The tay-sachs disease treatment market report covers multiple regions, such as Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse For More Similar Reports-

Alzheimer's Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/alzheimer-disease-treatment-global-market-report

Inflammatory Bowel Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Lysosomal Disease Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/lysosomal-disease-treatment-global-market-report

Learn more about <u>The Business Research Company</u>: With more than 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has earned a reputation for providing comprehensive, data-rich research and insights. Equipped with 1,500,000 datasets, the firm leverages in-depth secondary research and unique insights from industry leaders to provide the information you need to stay ahead of the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/ Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708 Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham The Business Research Company +44 20 7193 0708 info@tbrc.info Visit us on social media:

Facebook

Χ

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/797963813

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.